This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation. 2017; 135: 241-250.

Published: 2nd August 2017

Authors: Schuyler Jones W, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ et al.

Conclusion

Some 7875 patients with a previous lower limb revascularization procedure were randomized, and followed for a median of 30 months to a composite end point including cardiovascular death, heart attack or stroke. The end point was reached by 11.4 per cent of treated patients and 11.3 per cent of controls.

Pubmed Link

You may also be interested in

Scientific Surgery

Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020; 383: 207-217.

Authors: Claiborne Johnston S, Amarenco P, Denison H, Evans SR, Himmelmann A, James S et al.

Scientific Surgery

Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004.

Authors: Bonaca MP, Bauersachs RM, Anand S, Debus ES, Nehler MR, Patel MR et al.

Scientific Surgery

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020; 395: 1487-1495.

Authors: Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C et al.

Scientific Surgery

Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. The COMPASS Trial. Circulation 2019; 140: 529-537

Authors: Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK et al.

Scientific Surgery

No clinical benefit of intramuscular delivery of bone marrow-derived mononuclear cells in nonreconstructable peripheral arterial disease: results of a phase-III randomized-controlled trial. Ann Surg 2018; 268: 756-761.

Authors: Lindeman J, Zwaginga J, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ et al.

Scientific Surgery

A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. J Vasc Surg 2018; 67: 1922-1932.

Authors: Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS et al.

Scientific Surgery

Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215-225.

Authors: Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ et al.

Scientific Surgery

Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387–399.

Authors: Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC et al.

Scientific Surgery

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229.

Authors: Anand S, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al.

Scientific Surgery

Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2017; 12: e0175283.

Authors: Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA et al.

Scientific Surgery

Evaluation of cell therapy on exercise performance and limb perfusion in peripheral artery disease. Circulation. 2017; 135: 1417-1428.

Authors: Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC et al.

Scientific Surgery

Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330.

Authors: Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al.